Stay updated with breaking news from Hepatitis Delta. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Late-breaker SOLSTICE data abstract accepted for poster presentation at the European Association for the Study of the Liver Congress 2024 – – Two additional hepatitis program data readouts...
– Prior data from the Phase 2 SOLSTICE trial in chronic hepatitis delta participants demonstrated that after only 12 weeks of combination therapy, 100% of participants had HDV RNA less than the...
Vir Biotechnology, Inc. today announced that Executive Vice President, and Chief Medical Officer, Phil Pang, M.D., Ph.D., has decided to leave the company at the end of March 2024 to spend more time...
20.02.2024 - Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Executive Vice President, and Chief Medical Officer, Phil Pang, M.D., Ph.D., has decided to leave the company at the end of March 2024 to spend more time with his family. The Company has ...
Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2023 Earnings Call Transcript November 2, 2023 Vir Biotechnology, Inc. misses on earnings expectations. Reported EPS is $-1.22 EPS, expectations were $-1.21. Operator: Hello, and welcome to Vir Biotechnology’s Third Quarter 2023 Financial Results and Business Update Call. As a reminder, this conference call is being recorded. At this time, […]